Volume 6.06 | Feb 20

Prostate Cell News 6.06 February 20, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
 
TOP STORY
New Study Reveals How to Improve Chemotherapy Use in Prostate Cancer
Researchers have found that a newer member of the taxane family called cabazitaxel, an FDA approved drug, has properties that could make it more effective for some patients – a hypothesis currently being tested in clinical trials. [Press release from Thomas Jefferson University discussing publication in Clinical Cancer Research] Press Release | Abstract
Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells
Scientists used the LNCaP prostate cancer cell line, which harbors the androgen receptor mutation most commonly detected in castrate-resistant tumors, analysing alterations in the proteome and comparing these to the effect of these therapeutics upon androgen receptor activity and cell proliferation. [Mol Cell Proteomics] Abstract | Full Article

Autophagy Modulates the Effects of Bis-Anthracycline WP631 on p53-Deficient Prostate Cancer Cells
Treatment of p53-deficient PC-3 human prostate carcinoma cells with nanomolar concentrations of bis-anthracycline WP631 induced changes in gene expression, which resulted in G2/M cell cycle arrest, autophagy and cell death. [J Cell Mol Med] Full Article

IL-17 and Insulin/IGF1 Enhance Adhesion of Prostate Cancer Cells to Vascular Endothelial Cells through CD44-VCAM-1 Interaction
Human umbilical vein endothelial cells (HUVECs) and human prostate cancer cell lines were analyzed for expression of vascular cell adhesion molecule 1 (VCAM-1), integrins, and cluster of differentiation 44 (CD44) using flow cytometry and Western blot analysis. The effects of interleukin-17 (IL-17), insulin, and insulin-like growth factor 1 (IGF1) on VCAM-1 expression and adhesion of prostate cancer cells to HUVECs were examined. [Prostate] Abstract

Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression
Researchers provide evidence of a role for the newly characterized glutamate family member GPR158 in prostate cancer (PCa) growth and progression. They found that GPR158 promotes PCa cell proliferation independent of androgen receptor functionality and that this requires its localization in the nucleus of the cell. [PLoS One] Full Article

p,p′-Dichlorodiphenyltrichloroethane (p,p′-DDT) and p,p′-Dichlorodiphenyldichloroethylene (p,p′-DDE) Repress Prostate Specific Antigen Levels in Human Prostate Cancer Cell Lines
Scientists determined whether environmentally relevant concentrations of p,p′-DDT and p,p′-DDE negatively impact androgen receptor (AR)-regulated expression of prostate-specific antigen, and other AR target genes in human LNCaP and VCaP prostate cancer cells. [Chem Biol Interact] Abstract

CC-Chemokine Receptor 7 Is Overexpressed and Correlates with Growth and Metastasis in Prostate Cancer
Scientists investigated the expression and clinical significance of CC-chemokine receptor 7 in a large collection of prostate cancer (PCa) samples and explored its function on the proliferation and migration of PCa cells. [Tumor Biol] Abstract

Anti-Proliferative Effect and Induction of Apoptosis in Androgen-Independent Human Prostate Cancer Cells by 1,5-Bis(2-Hydroxyphenyl)-1,4-Pentadiene-3-One
Researchers determined the anti-cancer properties of four selected curcumin analogues, on the cytotoxicity, proliferative and apoptotic effects on androgen-independent human prostate cancer cells. [Molecules]
Abstract | Download Full Article

CLINICAL RESEARCH

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy plus Radiotherapy versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
Scientists previously reported that radiotherapy added to androgen-deprivation therapy improves survival in men with locally advanced prostate cancer. Here, they report the prespecified final analysis of this randomized trial. [J Clin Oncol] Full Article

Neoadjuvant Luteinizing-Hormone-Releasing Hormone Agonist plus Low-Dose Estramustine Phosphate Improves Prostate-Specific Antigen-Free Survival in High-Risk Prostate Cancer Patients: A Propensity Score-Matched Analysis
Researchers used a retrospective design via propensity score matching to elucidate the clinical benefit of neoadjuvant luteinizing-hormone-releasing hormone agonist plus low dose estramustine phosphate for high-risk prostate cancer. [Int J Clin Oncol] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
 
REVIEWS
Prostate Cancer Vaccines: The Long Road to Clinical Application
To induce long-lasting clinical responses, vaccines will need to be combined with immunoregulatory agents to overcome tumor-related immune suppression. Immunotherapy, as a treatment modality for prostate cancer, has received significant attention in the past few years. [Cancer Immunol Immunother] Abstract

Molecular Imaging of Prostate Cancer: Translating Molecular Biology Approaches into the Clinical Realm
The authors discuss advanced imaging techniques that allow direct visualisation of molecular interactions relevant to prostate cancer and their potential for translation to the clinical setting in the near future. [Eur Radiol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers
Alethia Biotherapeutics Inc. announced that it has submitted a CTA with Health Canada to initiate a Phase I clinical trial with AB-16B5, a fully humanized monoclonal antibody that inhibits epithelial to mesenchymal transition (EMT). [Alethia Biotherapeutics Inc.] Press Release

Kaul Foundation Donates $7 Million for UAB Personalized Medicine Institute
The Hugh Kaul Foundation has donated $7 million to the University of Alabama at Birmingham (UAB) to establish the Hugh Kaul Personalized Medicine Institute at UAB. [University of Alabama at Birmingham]
Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW EMBO | EMBL Symposium: Frontiers in Stem Cells & Cancer
March 29-31, 2015
Heidelberg, Germany

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW PhD Studentship – Prostate Cancer (University of Hull)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Cancer Biology (Brigham & Women’s Hospital – Harvard Medical School)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Research – Scientist Metabolic Adaptation in Treatment Resistant Prostate Cancer (Cancer Research UK Beatson Institute in Glasgow)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us